

ASX ANNOUNCEMENT

Positive interim results achieved in HeraCARE paid pilot with US-based Obstetrix® Medical Group, second pilot site confirmed

- Paid pilot with Obstetrix Medical Group (Obstetrix), one of the largest clinical services
 providers specialising in women's and children's care, has been underway for 8 weeks in
 San Jose, California.
- Interim results, adherence levels and feedback from both expecting mothers and clinicians have all been very positive.
- 89% Overall very positive patient adherence rate to the HeraCARE care plan.
- 100% of the professional care team (physicians and midwives) indicated they believe the
 HeraCARE platform is safe, effective and improves the standard of care and that they enjoy
 offering the solution to their patients.
- 100% of the professional care team answered they would recommend the HeraCARE platform to other care teams.
- The second pilot site will be the Obstetrix practice in Atlanta, Georgia, and shipment of the hardware is planned for September 15.
- These results have been de-identified and anonymized according to the US HIPAA (Health Insurance Portability and Accountability Act) compliant for privacy.

Patient Satisfaction scores have been very positive:

- **100% of patients answered 'True'** to the question: "Have you enjoyed the experience of taking your measurements remotely and more often?"
- **100% of patients answered 'True'** to the question: "Do you feel supported by your care team and this program?"
- **95% answered 'True'** to the question: "Have you enjoyed the content you have been assigned and have read?"
- **90% answered 'Definitely' or 'Yes'** to the question: "Has HeraCARE contributed to peace of mind during your pregnancy?"
- 84% (4.2 out of 5) Overall patient experience score for the HeraCARE solution.
- 95% (4.8 out of 5) Overall professional care team score for the HeraCARE solution.

HeraMED Limited (ASX:HMD) ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care, is pleased to provide interim results from the paid pilot with Obstetrix Medical Group, an affiliate of Mednax. Listed on the NYSE, with a market capitalisation of over US\$2.7 billion, Mednax is one of the largest providers of women's and children's physician services in the U.S. via its network of over 2,300 physicians in 39 states and



Puerto Rico. Mednax-affiliated clinicians and their practices provide vital care or diagnostics to 1 in 4 babies born in the U.S. Mednax companies and solutions include Pediatrix Medical Group, the nation's leading provider of maternal-fetal, newborn and pediatric subspecialty services, and Obstetrix Medical Group, a provider of obstetric and maternal-fetal services.

Santosh Pandipati, M.D., FACOG, maternal-fetal medicine specialist at Obstetrix Medical Group of San Jose, said:

"Results and overall system performance have been excellent and illustrate the value of the HeraCARE technology. We are very pleased with the feedback received thus far by expectant mothers, their compliance to the care plan, their excitement about joining a virtual OB program and their ability to easily monitor the health of their pregnancy remotely. We are continually searching for technology to complement and improve our existing care models, and we believe the HeraCARE solution can indeed create a revolution in pregnancy care."

Lee Wood, Senior Vice President of National Operations for Mednax said:

"We are excited with the results and performance of the HeraCARE system, and the feedback we continue to receive from our clinical team as well as our valuable customers is very positive. We look forward to exploring additional collaboration opportunities with HeraMED."

HeraMED CEO and Cofounder, Mr. David Groberman, said: "Our focus throughout the development of the HeraBEAT smart pregnancy monitor and HeraCARE platform was to make our technology easy to use and deliver an improved holistic experience for expectant mothers while ensuring safety, accuracy and the highest level of quality. I am very excited about these interim results as they clearly demonstrate that we have accomplished our primary goals, as evidenced by the decision by Obstetrix to undertake a second paid pilot in Atlanta, Georgia.

"In parallel with the pilot, we have worked closely with Obstetrix and their professional team to ensure the system is effective, optimised to their needs and integrated seamlessly into their workflows. We continue to focus on this collaborative work as well as planning a rollout across the US," he said.

About Obstetrix Medical Group

Obstetrix Medical Group, a Mednax affiliate, is a provider of obstetric and maternal-fetal services, dedicated to improving patient outcomes. Hospitals and clinicians partner with us to collaborate in the care of pregnant and labouring women through office and hospital-based maternal-fetal services and OB/GYN hospitalist programs.

As a national, multi-specialty medical group, our clinicians collaborate across the care continuum, from conception to birth and beyond, to deliver high-quality, evidence-based, cost-effective care. Our specialty-driven education and clinical programs support clinicians and hospitals in achieving better maternal and fetal outcomes while reducing care costs.



About Mednax

Mednax, Inc. is a national medical group comprised of the nation's leading providers of physician services. Physicians and advanced practitioners practising as part of Mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico. Additional information is available at www.mednax.com.

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited CEO and Co-Founder David Groberman M: +972 52 6991188

E: David@hera-med.com

Company Secretary

Jonathan Hart T: +61 2 7251 1888

E: Jonathan@hera-med.com

Investors

Tim Chapman PAC Partners

M: +61 419 897 062

E: tchapman@pacpartners.com.au

About HeraMED Limited (ASX:HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.

About HeraCARE

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.